胰岛素联合罗格列酮或二甲双胍治疗后对2型糖尿病患者血糖及体脂分布的影响

Effects of Insulin plus Rosiglitazone or Metformin on Blood Glucose and Body Fat Distribution in Patients with Type 2 Diabetes Mellitus.

目的:比较胰岛素联合罗格列酮与胰岛素联合二甲双胍治疗后对2型糖尿病患者血糖及体脂分布的影响。方法:将符合纳入标准的2型糖尿病患者60例随机分成A、B两组,A组给予胰岛素联合罗格列酮(n=30)治疗,B组给予胰岛素联合二甲双胍治疗(n=30)共8周。治疗前后测身高、体重、腰围、臀围、空腹血糖、餐后2h血糖及糖化血红蛋白。结果:两组治疗前后FBG、PPG、HbA1c均有降低,有统计学意义(P<0.05);罗格列酮组治疗前后臀围、体重、体重指数增加,有统计学意义(P<0.05),腰围增加不明显,腰臀比下降,但差异无统计学意义(P>0.05);二甲双胍组治疗前后腰围、臀围、体重、体重指数均有降低,但差异无统计学意义(P>0.05)。结论:无论胰岛素联合罗格列酮还是胰岛素联合二甲双胍治疗,均可降低2型糖尿病患者的血糖和糖化血红蛋白,罗格列酮治疗可使2型糖尿病患者臀围、体重和体重指数增加,似有脂肪重分布的趋势,二甲双胍治疗对2型糖尿病患者臀围、腰臀比、体重、体重指数及体脂分布无明显影响。

Objectives： To compare the effects of insulin plus rosiglitazone and insulin plus metformin on blood glucose and body fat distribution in patients with type 2 diabetes mellitns.Methods： Sixty patients with type 2 diabetic were recruited and divided into group A and group B randomly. The group A （ n = 30） received insulin pins rosiglitazone, and the group B （ n = 30） received insulin plus metformin for 8 weeks. The height, body weight, body mass index （BMI）, waist circumference, hip circumference, ratio of waist circumference to hip circumference （WHR）, fasting blood glucose （FBG）, 2-hour postprandial blood glucose （PPG） and HbA1c were measured at the beginning and at the end of treatment. Results： The results revealed the levels of FBG, PPG and HbA1c decreased obviously in the two groups （P 〈 0.05） . In the rosiglitazone group, the hip circumference, body weight and BMI increased significantly （P 〈 0.05）, the waist circumference increased and WHR decreased, but there were no statistical differences （ P 〉 0.05） . In the mefformin group, the waist circumference, hip circumference, WHR weight and BMI decreased, but there were no significant difference （ P 〉 0.05） . Conclusions ： The levels of FBG, PPG and HbAlc decrease in both insulin pins rosiglitazone group and insulin plus mefformin group. The rosiglitazone can increase hip circumference, body weight, BMI and it seems has tendency of body fat redistribution. Metformin have no effects on hip circumference, WHR, body weight, BMI and body fat distribution in patients with type 2 diabetes mellitus.